AavantiBio, Aldevron partner on gene therapy

By The Science Advisory Board staff writers

July 21, 2021 -- Aldevron made a deal to supply plasmid DNA that will enable AavantiBio to advance its gene therapies for rare genetic diseases.

Aldevron will supply plasmids to AavantiBio's planned vector core and contract development manufacturing organization partners. Also, the partnership includes materials for proof-of-concept and good lab practices (GLP) toxicology studies for future programs.

Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as...
Aldevron adds AAV plasmid product offerings
Aldevron has launched rep/cap plasmids to support adeno-associated virus (AAV) vector manufacturing.

Copyright © 2021 scienceboard.net

Bio-IT World Conference and Expo
September 20-22
Boston, Massachusetts United States
BioProcess International
September 20-23
Boston, Massachusetts United States
Cell and Gene Therapy Manufacturing and Commercialization
September 20-23
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter